Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study

  • Oramed Pharmaceuticals Inc's ORMP subsidiary, Oravax Medical Increported preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate.
  • Preliminary Phase 1 trial results from the first cohort include:
    • Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in most patients dosed.
    • No safety issues were observed, including mild symptoms.
  • An open-label, Phase 1 trial will evaluate the safety, tolerability, and immunogenicity of two concentrations of the COVID-19 vaccine administered orally as a two-dose schedule administered 21 days apart.
  • The first cohort of 12 eligible subjects received one capsule containing the low dose on day one and a second oral dose on day 21. The ongoing trial includes an additional 12 subjects (subjects 13-24) who will receive a high dose on day one and a second dose on day 21.
  • Subjects will be monitored for safety, tolerability, and antibody titers for 24 weeks after the first dose. An end-of-trial visit will take place 24 weeks after the first dose.
  • Price Action: ORMP shares are down 6.12% at $6.14 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!